SalPyr-2

**SalPyr-2** is an experimental **salicylanilide 5-chloropyrazinoate small molecule** reported in medicinal chemistry research as part of a series of substituted salicylanilide derivatives evaluated for **anticancer activity in glioblastoma**. In the cited study, SalPyr-2 decreased viability of U87 human glioblastoma cells, and salicylanilide compound-induced cell death was associated with **autophagy activation**. It appears to be a preclinical research compound rather than a clinically developed therapeutic, with no clear evidence from the provided source of commercial development, formal manufacturer assignment, or a validated single molecular target beyond its characterization as a salicylanilide derivative with in vitro antitumor activity.

Other names

salicylanilide 5-chloropyrazinoatesalicylanilide5-chloropyrazinoatesalicylanilide-5-chloropyrazinoate